Serum conversion pattern of SCC-Ag levels between pre- and post-chemoradiotherapy predicts recurrence and metastasis in cervical cancer: a multi-institutional analysis

The value of squamous-cell carcinoma antigen (SCC-Ag) as a tumor marker for cervical cancer is controversial because it is not elevated (> 2 ng/mL) in a quarter of patients at diagnosis. Two hundred ninety one IB-IVA cervical squamous cell-carcinoma patients who underwent definitive chemoradiothe...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & experimental metastasis 2021-10, Vol.38 (5), p.467-474
Main Authors: Lee, Sea-Won, Hong, Ji Hyung, Yu, Mina, Jeong, Songmi, Kim, Sung Hwan, Kim, Yeon-Sil, Lee, Sung Jong, Lee, Jong Hoon
Format: Article
Language:English
Subjects:
Antigens
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cervical cancer
Cervix
Chemoradiotherapy
Chemotherapy
Conversion
Hematology
Metastases
Multivariate analysis
Oncology
Patients
Radiation Oncology
Radiation therapy
Research Paper
Squamous cell carcinoma
Surgical Oncology
Survival
Tumor markers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The value of squamous-cell carcinoma antigen (SCC-Ag) as a tumor marker for cervical cancer is controversial because it is not elevated (> 2 ng/mL) in a quarter of patients at diagnosis. Two hundred ninety one IB-IVA cervical squamous cell-carcinoma patients who underwent definitive chemoradiotherapy (CRT) were included in four tertiary institutions. Serum conversion pattern between pre- and post-treatment SCC-Ag levels was categorized into the following three arms: (1) Consistent Seronegative arm (both ≤ 2 ng/mL); (2) Negative Conversion arm (from > 2 ng/mL to ≤ 2 ng/mL); and (3) Consistent Seropositive arm (both > 2 ng/mL). Median follow-up time was 40.3 months. For Consistent Seronegative ( N  = 67), Negative Conversion ( N  = 165), and Consistent Seropositive ( N  = 59) arms, the 3-year recurrence-free survival (RFS) rates were 79.4%, 62.0%, and 48.4% ( P  
ISSN:0262-0898
1573-7276
DOI:10.1007/s10585-021-10115-w